To confirm the relationship between IL-23 and IL-36γ in vivo, we retrospectively reviewed the skin biopsies obtained from psoriasis patients who underwent anti-IL12/23 p40 monoclonal antibody (ustekinumab, Stelara®) treatment and compared them with psoriasis patients who received oral methotrexate therapy. Here, IL36G is linked to psoriasis.